Your browser doesn't support javascript.
loading
Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab).
McKnight, Brooke N; Kuda-Wedagedara, Akhila N W; Sevak, Kuntal K; Abdel-Atti, Dalya; Wiesend, Wendy N; Ku, Anson; Selvakumar, Dakshnamurthy; Carlin, Sean D; Lewis, Jason S; Viola-Villegas, Nerissa T.
Affiliation
  • McKnight BN; Department of Oncology, Karmanos Cancer Institute, 4100 John R. Street, Detroit, MI, 48201, USA.
  • Kuda-Wedagedara ANW; Department of Oncology, Karmanos Cancer Institute, 4100 John R. Street, Detroit, MI, 48201, USA.
  • Sevak KK; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Abdel-Atti D; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Wiesend WN; Department of Anatomic Pathology, Beaumont Hospital, 3601 West 13 Mile Road, Royal Oak, MI, 48073, USA.
  • Ku A; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Selvakumar D; Department of Oncology, Karmanos Cancer Institute, 4100 John R. Street, Detroit, MI, 48201, USA.
  • Carlin SD; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Lewis JS; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Viola-Villegas NT; Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Sci Rep ; 8(1): 9043, 2018 06 13.
Article in En | MEDLINE | ID: mdl-29899472
ABSTRACT
Tumor resistance to treatment paved the way toward the development of single agent drugs that target multiple molecular signatures amplified within the malignancy. The discovered crosstalk between EGFR and HER3 as well as the role of HER3 in mediating EGFR resistance made these two receptor tyrosine kinases attractive targets. MEHD7945A or duligotuzumab is a single immunotherapy agent that dually targets both molecular signatures. In this study, a positron emission tomography (PET) companion diagnostic to MEHD7945A is reported and evaluated in pancreatic cancer. Tumor accretion and whole body pharmacokinetics of 89Zr-MEHD7945A were established. Specificity of the probe for EGFR and/or HER3 was further examined.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Immunoglobulin G / Receptor, ErbB-3 / Positron-Emission Tomography Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Sci Rep Year: 2018 Document type: Article Affiliation country: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Immunoglobulin G / Receptor, ErbB-3 / Positron-Emission Tomography Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Sci Rep Year: 2018 Document type: Article Affiliation country: Estados Unidos